-
Innovation Ranking
NewInnovation Ranking – Albireo Pharma Inc
Albireo Pharma Inc (Albireo), formerly Biodel Inc, It focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating...
-
Product Insights
Infusion Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Infusion Systems Pipeline Market Report Overview Infusion systems are used to administer medication to a patients in critical care, emergency care, home care, and trauma centres. The infusion systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SER-301 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SER-301 in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SER-301 in Ulcerative Colitis Drug Details: SER-301 is under development for...
-
Company Insights
Innovation and Patenting activity of Albireo Pharma Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Albireo Pharma Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Albireo Pharma Inc – Company Profile
Albireo Pharma Inc (Albireo), formerly Biodel Inc, It focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc, A3384 for bile acid malabsorption, and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating...
Add to Basket -
Product Insights
Net Present Value Model: Bylvay
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Bylvay Drug Details Odevixibat Sesquihydrate (Bylvay)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – odevixibat
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry odevixibat Drug Details Odevixibat Sesquihydrate (Bylvay) is acts by targeting ileal bile acid transporter...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – A-3907
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry A-3907 Drug Details A-3907 is under development for the treatment of adult cholestatic liver...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – elobixibat
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry elobixibat Drug Details Elobixibat (AJG533, A3309, Goofice) is a bile acid transport inhibitor. It...
-
Product Insights
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...